Mutations in the p53 tumor suppressor gene are observed in up to 50% of all tumors and represent one of the most common genetic alterations in cancer. The high rate of spontaneous tumor development in p53-deficient mice was therefore not unexpected. 1 However, considering the central role of p53 as a regulator of cellular proliferation and homeostasis, as well as cell death and premature senescence, the viability of p53 null mice and the abscence of developmental defects came as a surprise. 1 Apart from neural tube closure defects in approximately 16% of female p53 null mice and a reduced reproductive capacity of both genders no in vivo developmental abnormalities have been reported. 2 This is in striking contrast to the phenotype of p53 depletion in Xenopus embryos which leads to gastrulation failure and defects in mesoderm formation due to impaired TGF-b/Nodal/ activin gene responses. 3 A possible explanation for the different p53 knockout phenotype in Xenopus and mice is that p53 is only one member of a family of structurally and functionally related genes. In addition to p53, early mouse embryos express the p53 family members p63 and p73 that might compensate for the loss of p53, while in Xenopus p53 is solely responsible for early embryogenesis as p73 is not found in the lower vertebrates and Xenopus p63 is only expressed at later stages during organogenesis. 3 We know from mouse knockouts of the p63 and p73 genes that both are critical for developmental processes. p63 null mice are born alive but die shortly after birth due to severe defects in their limb, craniofacial and epithelial development. 4, 5 In contrast, p73 appears critical for aspects of neurogenesis, pheromone signaling, and reproduction, and the control of inflammatory responses. 6 Most of the p73-null mice die within 2 month after birth due to chronic infections and only about 25% survive to adulthood. 6, 7 However, there have been no reports on the in vivo effects of homozygous compound knockouts of the p53 family members.
All p53 family genes have been shown to generate transactivation-defective DN-isoforms lacking the aminoterminal transactivation domain. 6, [8] [9] [10] [11] These DN-isoforms are generated either by the use of alternative intronic promoters or by means of alternative splicing. [12] [13] [14] Since the DNisoforms retain their DNA-binding capacity, they bind to the promoters of target genes and act as transdominant-negative inhibitors of the full-length isoforms. 15 As shown in Figure 1a , N-terminally truncated p73a generated by both alternative splicing (DN AS ) or alternative promoter usage (DN AP ) functions as a potent inhibitor of all the major transactivating p53 family members (p53, TAp63 and TAp73).
The transactivation function of p53 family members is critical for various differentiation processes such as myogenic differentiation of myoblasts or neuronal differentiation of neuroblastoma cells in response to all-trans retinoic acid (ATRA). [16] [17] [18] Furthermore, exogenous expression of TAp73 is sufficient to induce morphological and biochemical markers of neuronal differentiation. 18 Whereas TAp73 enhances terminal differentiation of oligodendrocyte precursors, DNp73 inhibits this process. 19 During nephrogenesis, DNp73 is expressed preferentially in proliferating nephron precursors, whereas TAp73 is predominantly expressed in the differentiation domain of the renal cortex. 20 This spatiotemporal switch from DNp73 to TAp73 may play an important role not only in the regulation of terminal differentiation in the developing nephron but suggests general antagonistic roles in differentiation control for the different p53 family proteins.
In order to define the role of the p53 family inhibitor DNp73 in cellular differentiation and embryogenesis we analyzed the effects of deregulated DNp73 expression using both cell culture models for cellular differentiation and transgenic mice carrying a conditional DNp73 transgene. In murine C2C12 myoblasts myogenic differentiation induced by growth factor withdrawal is associated with increasing expression of all three p53 family members (Figure 1b) . Whereas p53 transcription progressively increases during the first 36 h, expression of TAp63 and TAp73 peaks between 6 and 12 h of differentiation. The TAp73 expression changes are specific and it has been shown, that TAp73 expression is actively repressed by the dEF1/ZEB repressor in proliferating C2C12 myoblasts and activated during differentiation by the muscle regulatory factors MyoD, myogenin, Myf5 and Myf6. 17 To inhibit the transactivation function of all three p53 family members during this differentiation program, we stably transduced C2C12 myoblasts with DNp73a by retroviral gene transfer. Whereas cells transduced with an empty retroviral vector (mock) arrest, elongate, align and fuse to form multinuclear myotubes that stain positive for myosin heavy chain (myHC) as a marker for differentiated muscle cells, DNp73a expressing C2C12 cells fail to differentiate (Figure 1c) . Similar results were obtained in primary human and murine myoblasts (data not shown). Although p53-null mice have no muscle phenotype, it has been previously shown that myogenic differentiation is reduced by loss or inhibition of p53 due to defective induction of the retinoblastoma protein RB. 16 The differentiation defect induced by transdominant-negative p53 (p53DD), however, is subtle compared to the complete block of myogenic differentiation www.nature.com/cdd observed with the pan-p53 family inhibitor DNp73a (Figure 1d ). This supports the hypothesis of functional redundancy within the p53 family with respect to developmental control of myogenesis.
It is known that bone morphogenetic protein-2 (BMP2) converts the myogenic differentiation pathway of C2C12 myoblasts into that of osteoblast lineage. 21 Consistently, differentiation of mock myoblasts in the presence of BMP2 almost completely inhibited the formation of multinucleated, myHC-expressing myotubes, and induced the appearance of numerous alkaline phosphatase (ALP)-and osteocalcinpositive cells (Figure 1e and f). DNp73a interfered not only with the myogenic differentiation program but also effectively inhibited BMP2-induced conversion into the osteoblast lineage (Figure 1e and f) .
Furthermore, TAp73 has been implicated in the regulation of neuronal differentiation providing an intriguing epxlanation for the neurological phenotype of p73-deficient mice. 22 Both induction of endogenous p73 by ATRA as well as ectopic expression of TAp73 isoforms have been shown to induce morphological and biochemical markers of neuronal differentiation in N1E-115 neuroblastoma cells. 18 Here we show, that DNp73a efficiently blocks ATRA-induced differentiation of SH-SY5Y neuroblastoma cells. Whereas ATRA-treatment induced extension of multiple neurites as a morphological marker and expression of neurofilament as a biochemical marker of neuronal differentiation in mock cells, this was significantly reduced in DNp73a transfectants (Figure 1g and h). These data clearly show that the p53 family inhibitor DNp73a is a potent repressor of differentiation in multiple experimental settings including myogenic, osteoblastic and neuronal differentiation.
To analyze the effect of p53 family inhibition in vivo we generated mice transgenic for the DNp73a-isoform obtained by alternative splicing of exon 2. We first attempted to create transgenic mice using the ubiquitously active HMG-CoAreductase promoter, but repeatedly failed to obtain founder mice that expressed the transgene although other transgenic lines were readily obtained with this promoter. Considering that DNp73a might interfere with some essential developmental processes we cloned a conditional DNp73a transgene construct (Figure 1i ) consisting of the broadly active b-actin promoter, followed by a GFP (green fluorescence protein)-stop cassette flanked by two loxP sites and preceeding a DNp73a cDNA coupled to a PLAP (human placenta-like ALP) cDNA via an internal ribosomal entry site (IRES). Excision of the GFP expression cassette by Cre recombinase efficiently induced DNp73a protein expression in transfected H1299 cells (Figure 1j ). In the inactive state the transgene failed to inhibit transactivation of a p53-dependent reporter construct . In detail, H1299 cells were cotransfected with 200 ng luciferase reporter plasmid containing p53 consensus binding sites, 25 50 ng p53, TAp63g or TAp73b expression plasmid 26 and 400 ng of the indicated DNp73a plasmid. 27 Luciferase activity was determined 48 h after transfection. (b) C2C12 cells were induced to differentiate into myotubes by incubation in medium containing 2% horse serum. RNA was isolated from the cells at the indicated time points (h) and expression of p53, TAp63 and TAp73 was measured by semiquantitative RT-PCR. Expression of the housekeeping gene GAPDH is shown as a control. (c) C2C12 cells were transduced with retrovirus generated by transient transfection of the amphotropic packaging cell line PT67 (Becton Dickinson) with either empty vector (mock) or the pQCXIP-DNp73a vector. Transduced cells were selected in growth medium containing 1.5 mg/ml puromycin. Cells were either grown in growth medium or differentiated for 5 days with 2% horse serum. Differentiation into multinuclear myotubes was analyzed by immunofluorescence staining for myosin heavy chain (MF 20 antibody, Developmental Studies Hybridoma Bank). Nuclei were counterstained with DAPI. (d) C2C12 myoblasts were stably transduced with retroviral vectors (mock, DNp73a or dominant-negative p53 p53DD) and analyzed for myosin heavy chain (myHC) expression by Western blot before and after induction of differentiation. (e) C2C12 myoblasts (mock or DNp73a) were differentiated for 5 days in medium containing 5% FCS in the absence or presence of 300 ng/ml BMP2 (kindly provided by Walter Sebald, University of Würzburg, Germany) and stained for the osteoblast marker gene alkaline phosphatase as described. 21 (f) C2C12 myoblasts treated as in (e) were analyzed by semiquantitative RT-PCR for expression of muscle (myHC) or osteoblast (alkaline phosphatase, AP; osteocalcin) marker genes. (g and h) SH-SY5Y neuroblastoma cells were transfected with pQCXIP (mock) or pQCXIP-DNp73a plasmids and selected in 1 mg/ml puromycin. Cells were induced to differentiate in 1 mM all-trans retinoic acid (ATRA), analyzed for (g) expression of the neuronal marker gene neurofilament by semiquantitative RT-PCR and (h) neurite extension by phase contrast microscopy. Sequences of primers used for RT-PCR are available upon request. flox transgenic mice as previously described 16 and cultured in Ham's F10 medium supplemented with 20% FCS and 2 ng/ml bFGF (Invitrogen). Cells were infected with 100 moi Adeno-Cre or Adeno-GFP as a control and either incubated in growth medium (GM) or induced to differentiate for 30 h in differentiation medium (DM) containing 2% horse serum (left panel: phase-contrast microscopic images; right panel: semiquantitative RT-PCR analysis of DNp73a, a 1 -actin, myosin heavy chain (myHC) and GAPDH expression). (n and o) Recombination of the DNp73a flox transgene can be induced in vivo. DNp73a flox transgenic mice were crossed to Mx1-Cre mice. 23 Cre expression in DNp73a flox /Mx1-Cre double transgenic offspring mice was left uninduced (-) or induced ( þ ) by three intraperitoneal injection of pI-pC (250 mg) at 2-day intervals. At 5 days after the last injection (n) DNA and (o) RNA was isolated from various tissues and analyzed for recombination efficiency by PCR with primers 1/5 and for DNp73a expression by RT-PCR with primers 4/5. Ta, tail; Sk, skin; Mu, muscle; Te, testis; In, intestine; Br, brain; Li, liver; Lu, lung; Sp, spleen; Th, thymus; NTC, no template control. (Figure 1m ) and correlates with defective expression of skeletal muscle marker genes such as a 1 -actin or myHC. This experiment shows that DNp73a expression is tightly repressed in the absence of Cre so that myogenic differentiation can proceed efficiently. It further shows that the inhibitory function of DNp73a on myogenic differentiation can be rapidly induced in primary muscle precursor cells and that it functions as predicted from our previous experiments in C2C12 myoblasts.
Regulation of DNp73a expression by Cre recombinase allows to specifically inhibit p53 family activity in a tissuespecific or time-controlled fashion. The conditional system for expression of DNp73a therefore provides a valuable model for studies aimed at assessing the role of the p53 family in cellular differentiation, tissue regeneration, embryonic development and tumorigenesis. To test if the transgene can be activated in vivo, we crossed DNp73a flox mice to Mx1-Cre mice that express Cre under control of the interferon-responsive promoter of the Mx1 gene. 23 Transient activation of the Mx1 promoter by intraperitoneal injections of the interferon inducer polyinosinic-polycytidylic acid (pI-pC) induces excision of the floxed GFP-stop cassette in a wide range of tissues resulting in efficient induction of DNp73a (Figure 1n and o) . Recombination efficiency varies depending on the tissue analyzed from less than 10% in the brain to more than 80% in the liver. This is in agreement with the recombination efficiencies reported for other floxed DNA sequences using the Mx1-Cre transgenic line. 23 To induce DNp73a expression during embryonic development, DNp73a-transgenic mice were crossed to Credeleter mice carrying a CMV-promoter driven Cre expression cassette on the X-chromosome. 24 In this strain expression of Cre has been shown to occur before implantation during early embryogenesis. Owing to the X-chromosomal location of the Cre-transgene, transgene transmission through males is restricted to female offspring. From matings of DNp73a flox transgenic mice to male Cre-deleter mice we obtained male DNp73-transgenic offspring at the expected Mendelian ratio. Consistent with the absence of a Cre allele in male offspring, the DNp73a transgene in these mice contained the floxed GFP-stop cassette. In contrast, no female DNp73a transgenic (i.e. DNp73a/Cre double transgenic) offspring were obtained from these matings. As a control, female transgenic mice with an excised GFP-stop cassette were readily obtained in parallel experiments with a different transgenic line. These data indicate that activation of DNp73a during early embryogenesis interferes with essential steps of embryonic development (Figure 1p ). It remains to be seen at which stage of development DNp73 interferes with embryogenesis and whether the phenotype resembles the phenotype of p53 knockdown in early Xenopus embryos. However, the phenotype of p53 family inhibition by DNp73a is more severe than any of the reported homozygous knockouts of single p53 family members and suggests significant functional redundancy and cooperativity within the p53 family in the coordination of embryonic development. Deregulated expression of the pan-p53 family inhibitor DNp73a therefore provides a first glance at the putative phenotype of a homozygous compound knockout of all three p53 family members.
